

Special Issue

Immune Biomarkers in Solid Tumors: From Peripheral Blood Parameters to Tissue-Based Indicators for Prognosis and Therapy Response

Message from the Guest Editors

The tumor microenvironment and systemic immune responses play critical roles in the progression, prognosis, and therapeutic response of solid malignancies. In recent years, the evaluation of peripheral blood immune parameters—such as immune cell subsets, cytokines, and soluble markers—has gained prominence as a minimally invasive approach to guide clinical decision-making. Concurrently, tissue-based immune biomarkers, including immune checkpoint molecules like PD-L1, have become integral components of predictive and prognostic models across a range of solid tumors. This Special Issue aims to highlight advances in the identification, validation, and clinical implementation of both circulating and histological immune biomarkers. We welcome original research, reviews, and perspectives focusing on the prognostic value, predictive utility, and mechanistic insights of immune biomarkers, with particular interest in studies that bridge systemic and tumor-localized immune profiling to optimize therapeutic strategies in solid tumors.

Guest Editors

Dr. Ioannis P. Trontzas

3rd Department of Internal Medicine, Sotiria General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

Prof. Dr. Konstantinos Syrigos

Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece

Deadline for manuscript submissions

31 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/240452

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)